SEARCH

SEARCH BY CITATION

References

  • 1
    National Centers for Disease Control and Prevention. Hepatitis C fact sheet. Available at: http://www.cdc.gov/ncidod/diseases/hepatitis/c/fact/html. Accessed November 2005.
  • 2
    Rosen HR. Hepatitis C pathogenesis: mechanisms of viral clearance and liver injury. Liver Transpl 2003; 9( Suppl): S35S43.
  • 3
    Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889896.
  • 4
    Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003; 9: 331338.
  • 5
    McHutchison JG, Fried MW. Current therapy for hepatitis C: pegylated interferon and ribavirin. Clin Liver Dis 2003; 7: 149161.
  • 6
    Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology 2003; 124: 17111719.
  • 7
    Rehermann B. Interaction between the hepatitis C virus and the immune system. Semin Liver Dis 2000; 20: 127141.
  • 8
    Rehermann B, Chisari FV. Cell mediated immune response to the hepatitis C virus. Curr Top Microbiol Immunol 2000; 242: 299325.
  • 9
    Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000; 132: 296305.
  • 10
    Takaki A, Wiese M, Maerten G, Depla E, Seifert U, Liebetrau A, et al. Cellular immune responses persist, humoral response responses decrease two decades after recovery from a single source outbreak of hepatitis C. Nat Med 2000; 6: 578582.
  • 11
    Seifert U, Liermann H, Racanelli V, Halenius A, Wiese M, Wedemeyer H, et al. Hepatitis C virus mutation affects proteasomal epitope processing. J Clin Invest 2004; 114: 250259.
  • 12
    Pavio N, Lai MM. The hepatitis C virus persistence: how to evade the immune system? J Biosci 2003; 28: 287304.
  • 13
    Tester I, Smyk-Pearson S, Wang P, Wertheimer A, Yao E, Lewinsohn DM, et al. Immune evasion versus recovery following acute hepatitis c virus infection from a shared source. J Exp Med 2005; 201: 17251731.
  • 14
    Hunziker IP, Zurbriggen R, Glueck R, Engler OB, Reichen J, Dai WJ, et al. Perspectives: towards a peptide-based vaccine against hepatitis C virus. Mol Immunol 2001; 38: 475484.
  • 15
    Rosen HR, Hinrichs DJ, Leistikow RL, Callender G, Wertheimer AM, Nishimura MI, et al. Cutting edge: identification of hepatitis C virus-specific CD8+ T cells restricted by donor HLA alleles following liver transplantation. J Immunol 2004; 173: 53555359.
  • 16
    Stauss HJ. Immunotherapy with CTLs restricted by nonself MHC. Immunol Today 1999; 20: 18201822.
  • 17
    Kaplan BLF, Yu DC, Clay TM, Nishimura MI. Redirecting T lymphocyte specificity using T cell receptor genes. Int Rev Immunol 2003; 22: 229253.
  • 18
    Roszkowski JJ, Yu DC, McKee MD, Cole DJ, McKee, MD, Nishimura MI. CD8 independent tumor cell recognition is a property of the T cell receptor and not the T cell. J Immunol 2003; 170: 25822589.
  • 19
    Roszkowski JJ, Lyons GE, Kast WM, Yee C, Van Besien K, Nishimura MI. Simultaneous generation of CD8+ and CD4+ melanoma reactive T cells by retroviral mediated transfer of a single TCR. Cancer Res 2005; 65: 15701576.
  • 20
    Kuball J, Schmitz FW, Voss RH, Ferreira EA, Engel R, Guillaume P, et al. Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. Immunity 2005; 22: 117129.
  • 21
    Topalian SL, Solomon D, Rosenberg SA. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol 1989; 142: 37143725.
  • 22
    Rivoltini L, Barracchini KC, Viggiano V, Kawakami Y, Smith A, Mixon A, et al. Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. Cancer Res 1995; 55: 31493157.
  • 23
    Anglard P, Trahan E, Liu S, Latif F, Merino MJ, Lerman MI, et al. Molecular and cellular characterization of human renal cell carcinoma cell lines. Cancer Res 1992; 52: 348356.
  • 24
    Langerman A, Callender GG, Nishimura MI. Retroviral transduction of peptide stimulated t cells can generate dual t cell receptor-expressing (bifunctional) t cells reactive with two defined antigens. J Transl Med 2004; 2: 42.
  • 25
    Nishimura MI, Kawakami Y, Charmley P, O'Neil B, Shilyansky J, Yannelli JR, et al. T-cell receptor repertoire in tumor-infiltrating lymphocytes. Analysis of melanoma-specific long-term lines. J Immunother 1994; 16: 8594.
  • 26
    Shilyansky J, Nishimura MI, Yannelli JR, Kawakami Y, Jacknin LS, Charmley P, et al. T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines. Proc Natl Acad Sci U S A 1994; 91: 28292833.
  • 27
    Clay TM, Custer MC, Sachs J, Hwu P, Rosenberg SA, Nishimura MI. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol 1999; 163: 507513.
  • 28
    Cole DJ, Weil DP, Shilyansky J, Custer M, Kawakami Y, Rosenberg SA, et al. Characterization of the functional specificity of a cloned T-cell receptor heterodimer recognizing the MART-1 melanoma antigen. Cancer Res 1995: 55: 748752.
  • 29
    Alexander-Miller MA, Leggatt GR, Berzofsky JA. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci U S A 1996; 93: 41024107.
  • 30
    Zeh HJ III, Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol 1999; 162: 989994.
  • 31
    Dudley ME, Nishimura MI, Holt AK, Rosenberg SA. Antitumor immunization with a minimal peptide epitope (G9–209-2M) leads to a functionally heterogeneous CTL response. J Immunother 1999; 22: 288298.
  • 32
    Irwin MJ, Heath WR, Sherman LA. Species-restricted interactions between CD8 and the alpha 3 domain of class I influence the magnitude of the xenogeneic response. J Exp Med 1989; 170: 10911101.
  • 33
    Newberg MH, Ridge JP, Vining DR, Salter RD, Engelhard VH. Species specificity in the interaction of CD8 with the alpha 3 domain of MHC class I molecules. J Immunol 1992; 149: 136142.
  • 34
    Wedemeyer H, He XS, Nascimbeni M, Davis AR, Greenberg HB, Hoofnagle JH, et al. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol 2002; 169: 34473458.